Cancer Research
MSK Research Drives 11 FDA Cancer Drug Approvals in 2025
Memorial Sloan Kettering-led trials produced 11 new FDA-approved cancer therapies in a single year, spanning multiple tumor types.
Drug Approval
May 19, 2026 0
Cancer
10 articles in this topic
Cancer Research
FDA Approves Sonrotoclax for Hard-to-Treat Mantle Cell Lymphoma
Sonrotoclax (Beqalzi), a next-gen BCL-2 inhibitor, wins accelerated FDA approval for relapsed or refractory MCL after BTK inhibitor failure.
Drug Approval
May 15, 2026 0
Cancer Research
FDA Approves Zenocutuzumab-zbco for Advanced Cholangiocarcinoma
The FDA approved zenocutuzumab-zbco for adults with advanced, unresectable, or metastatic cholangiocarcinoma, a rare and aggressive bile duct cancer with limited treatment options.
Drug Approval
May 13, 2026 0
Cancer Research
FDA Grants Expanded Approval to Zongertinib for HER2-Mutant Lung Cancer
The FDA expanded accelerated approval for zongertinib in HER2-mutant NSCLC, marking a targeted therapy milestone for a hard-to-treat mutation.
Drug Approval
May 6, 2026 0
Cancer Research
FDA Approves Zongertinib for HER2-Mutant Non-Small Cell Lung Cancer
Zongertinib (Hernexeos) wins FDA approval for unresectable or metastatic HER2-mutant non-squamous NSCLC, expanding targeted therapy options.
Drug Approval
May 1, 2026 0
Cancer Research
FDA Greenlights Two New HER2-Targeted Lung Cancer Drugs in Recent Months
Zongertinib and sevabertinib earn FDA accelerated approvals for HER2-mutant NSCLC, expanding targeted therapy options for a historically hard-to-treat subset.
Drug Approval
Apr 28, 2026 0
Cancer Research
FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant Lung Cancer
Zongertinib (Hernexeos) wins FDA accelerated approval for HER2-driven non-small cell lung cancer, offering a targeted oral option.
Drug Approval
Apr 21, 2026 0
Cancer Research
FDA Approves Keytruda Combo for Platinum-Resistant Ovarian Cancer
Pembrolizumab plus chemotherapy gains FDA approval for PD-L1-positive ovarian cancer patients who failed prior treatment.
Drug Approval
Apr 20, 2026 0
Cancer Research
FDA Approves Zongertinib for HER2-Mutant Lung Cancer in Landmark Targeted Therapy Win
Zongertinib (Hernexeos) wins accelerated FDA approval for metastatic NSCLC with HER2 tyrosine kinase domain mutations, filling a critical treatment gap.
Drug Approval
Apr 20, 2026 0
Cancer Research
FDA Approves Zongertinib for HER2-Mutated Lung Cancer in February 2026
New targeted therapy offers hope for patients with specific genetic mutations in non-small cell lung cancer.
Drug Approval
Apr 15, 2026 0